Related Experiment Video

Updated: Mar 19, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.8K

Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease

Christian Tanislav1, Dursun Guenduez2, Christoph Liebetrau3,4

  • 1Department of Neurology, Justus Liebig University, Giessen, Germany.

Plos One
|June 21, 2016
PubMed

Insights

Cardiac troponin I (cTnI) elevation is common in Fabry disease (FD) patients, indicating cardiac involvement. Continuous cTnI monitoring may benefit FD patients with cardiac complications.

Area of Science:

  • Cardiology
  • Genetics
  • Biochemistry

Background:

  • Fabry disease (FD) is a rare, X-linked, progressive genetic disorder caused by alpha-galactosidase deficiency.
  • Assessing cardiac involvement in FD is clinically challenging.
  • Cardiac troponin I (cTnI) is a potential biomarker for cardiac damage.

Purpose of the Study:

  • To evaluate the diagnostic value of cardiac troponin I (cTnI) in identifying cardiac involvement in Fabry disease patients.
  • To assess the correlation between elevated cTnI levels and clinical data in a large cohort of FD patients.

Main Methods:

  • Cardiac troponin I (cTnI) levels were measured using a sensitive assay in plasma samples from 62 FD patients.
  • Elevated cTnI levels (cut-off ≥0.04 ng/ml) were correlated with clinical data, including left ventricular hypertrophy (LVH).
  • A control group of non-FD patients with LVH was included for comparison.

Main Results:

  • Elevated cTnI levels were detected in 37% of FD patients, associated with older age and left ventricular hypertrophy (LVH).
  • Patients with LVH showed significantly higher cTnI levels (median 0.23 ng/ml vs. 0.02 ng/ml).
  • A cTnI level below 0.04 ng/ml demonstrated a high negative predictive value (97%) for the presence of LVH.

Conclusions:

  • Elevated cTnI levels are prevalent in FD patients and reflect cardiac involvement.
  • Continuous monitoring of cTnI may be beneficial for managing cardiac complications in Fabry disease.
  • cTnI shows promise as a biomarker for cardiac involvement in FD.
Abstract

More Related Videos

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum09:23

Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum

Published on: December 13, 2017

6.8K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
715
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
384
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
430
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
636